# PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct06157151/  
OnCo record `nct06157151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in cervical cancer, run by Precigen, Inc, now recruiting.

## Summary

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06157151 by Precigen, Inc, with 24 participants planned, started 2025-11-11 and due to reach its primary completion in 2026-11-11. Interventions recorded: PRGN-2009 plus Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06157151
- Phase: 2
- Setting: A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.
- Sponsor: Precigen, Inc
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06157151: https://clinicaltrials.gov/study/NCT06157151

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06157151.json